RenalytixAI, an in vitro diagnostics that uses artificial intelligence, has filed a submission to the FDA to clear KidneyIntelx. KidneyIntelx is designed to optimize clinical management and patient outcomes of kidney disease research as well as reduce costs and provide critical information to healthcare providers. If cleared, KidneyIntelx will be used in trials in conjunction with Type 2 diabetes and its effect on kidney failure, working to identify early stages of the disease.

Read more here.

More on: